HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

K Wakabayashi Selected Research

ONO 8711

12/2001Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.
11/2001Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis.
8/2000Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


K Wakabayashi Research Topics

Disease

19Carcinogenesis
01/2018 - 01/2000
19Neoplasms (Cancer)
01/2018 - 01/2000
9Colonic Neoplasms (Colon Cancer)
08/2004 - 01/2000
8Aberrant Crypt Foci
08/2004 - 01/2000
7Parkinson Disease (Parkinson's Disease)
12/2011 - 01/2000
5Multiple System Atrophy
10/2004 - 01/2000
5Carcinoma (Carcinomatosis)
08/2004 - 09/2000
5Body Weight (Weight, Body)
12/2001 - 03/2000
5Liver Neoplasms (Liver Cancer)
07/2001 - 03/2000
4Infections
01/2019 - 07/2001
4Neurodegenerative Diseases (Neurodegenerative Disease)
02/2012 - 07/2001
4Adenocarcinoma
10/2000 - 01/2000
3Dementia (Dementias)
01/2020 - 03/2001
3Lewy Body Disease (Lewy Body Dementia)
12/2011 - 07/2000
3Inflammation (Inflammations)
08/2001 - 02/2001
3Alzheimer Disease (Alzheimer's Disease)
06/2000 - 01/2000
2Virus Diseases (Viral Diseases)
01/2019 - 05/2005
2Intestinal Polyps
08/2004 - 01/2000
2Breast Neoplasms (Breast Cancer)
12/2001 - 01/2001
2Fibrosis (Cirrhosis)
09/2001 - 01/2001
2Liver Diseases (Liver Disease)
08/2001 - 06/2001
2Hepatocellular Carcinoma (Hepatoma)
06/2001 - 03/2000
2Adenoma (Adenomas)
08/2000 - 07/2000
2Autolysis
04/2000 - 01/2000
1Spinocerebellar Ataxias (Spinocerebellar Ataxia)
04/2014
1Sarcoma (Soft Tissue Sarcoma)
06/2012
1Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
02/2012
1Cholangitis
03/2009
1Granuloma
03/2009
1Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
03/2009
1Atrial Fibrillation
01/2006
1Pain (Aches)
01/2006
1Metaplasia
06/2005
1Leukemia
05/2004
1Bites and Stings (Sting)
05/2003
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2003
1Tongue Neoplasms (Tongue Neoplasm)
01/2003
1Pure Autonomic Failure
12/2002

Drug/Important Bio-Agent (IBA)

10alpha-SynucleinIBA
10/2004 - 01/2000
9Proteins (Proteins, Gene)FDA Link
02/2012 - 03/2000
9AzoxymethaneIBA
06/2005 - 01/2000
7benzocycloheptapyridineIBA
06/2005 - 03/2000
72- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA
06/2005 - 03/2000
6CarcinogensIBA
06/2005 - 01/2000
6ProstaglandinsIBA
08/2004 - 01/2000
5Messenger RNA (mRNA)IBA
08/2004 - 01/2001
4Prostaglandin E Receptors (Prostaglandin E Receptor)IBA
08/2004 - 08/2000
4nimesulide (Aulin)IBA
01/2003 - 01/2000
4Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
01/2003 - 01/2000
4EnzymesIBA
05/2001 - 05/2000
4Cyclooxygenase 2 (Cyclooxygenase-2)IBA
08/2000 - 05/2000
3Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
01/2003 - 09/2000
3ONO 8711IBA
12/2001 - 08/2000
3InterferonsIBA
07/2001 - 01/2001
3beta CateninIBA
08/2000 - 06/2000
2Double-Stranded RNA (RNA, Double Stranded)IBA
01/2019 - 05/2005
2AntibodiesIBA
12/2011 - 03/2009
2UbiquitinIBA
02/2005 - 03/2001
2Prostaglandins EIBA
08/2004 - 12/2001
2LipopolysaccharidesIBA
05/2004 - 05/2001
2Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
01/2003 - 07/2000
2Complement System Proteins (Complement)IBA
10/2001 - 08/2000
2CytokinesIBA
07/2001 - 05/2001
2Histone Deacetylase InhibitorsIBA
06/2001 - 03/2000
2Butyric Acid (Butanoic Acid)IBA
06/2001 - 03/2000
2Codon (Codons)IBA
08/2000 - 06/2000
2NG-Nitroarginine Methyl Ester (L-NAME)IBA
01/2000 - 01/2000
2Nitric Oxide Synthase (NO Synthase)IBA
01/2000 - 01/2000
1eIF-2 Kinase (eIF 2 Kinase)IBA
01/2019
1MicroRNAs (MicroRNA)IBA
01/2019
1Antiviral Agents (Antivirals)IBA
01/2019
1RNA Polymerase IIIIBA
01/2019
1A-Form DNA (A-DNA)IBA
01/2018
1norharmanIBA
01/2018
1polyglutamineIBA
04/2014
1RNA-Binding Protein FUSIBA
06/2012
1Myelin Basic ProteinIBA
12/2011
1SynucleinsIBA
12/2011
1Oxidoreductases (Dehydrogenase)IBA
03/2009
1XenobioticsIBA
03/2009
1Pyruvic Acid (Pyruvate)IBA
03/2009
1Morphine (MS Contin)FDA LinkGeneric
01/2006
1Excitatory Amino AcidsIBA
01/2006
1Pharmaceutical PreparationsIBA
01/2006
1Opioid Analgesics (Opioids)IBA
01/2006
1Glutamic Acid (Glutamate)FDA Link
01/2006
1Poly I-CIBA
05/2005
1DecitabineFDA Link
08/2004
1ONO AE 248IBA
08/2004
1Tretinoin (Retinoic Acid)FDA LinkGeneric
05/2004
1Hormones (Hormone)IBA
04/2003
1PolyaminesIBA
01/2003
1Drinking WaterIBA
01/2003
14-Nitroquinoline-1-oxide (4 Nitroquinoline 1 oxide)IBA
01/2003
1Proliferating Cell Nuclear Antigen (PCNA)IBA
01/2003

Therapy/Procedure

4Chemoprevention
10/2000 - 01/2000
3Therapeutics
10/2001 - 06/2001
1Sympathectomy (Sympathectomies)
01/2020
1Transjugular Intrahepatic Portasystemic Shunt
05/2003
1Denervation
12/2002